Similar to our drug screening results, several other tyrosine kinase receptor inhibitors (dasatinib [45], pazopanib [46], sunitinib [47], and sorafenib [48]) have anti-liposarcoma activity and are in clinical trials. The gene discussed is NTRK1; the disease is liposarcoma.